Related Experiment Video

Updated: Mar 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Afatinib treatment in advanced non-small cell lung cancer

Jane L Hurwitz1, Paula Scullin1, Lynn Campbell1

  • 1Department of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UK.

Lung Cancer (Auckland, N.Z.)
|February 18, 2017
PubMed

Insights

Afatinib, an irreversible EGFR inhibitor, shows promise in treating advanced non-small cell lung cancer (NSCLC). While improving progression-free survival, its impact on overall survival requires further investigation.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) still has a poor prognosis despite recent therapeutic advances.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) offer a new treatment option for NSCLC.
  • Resistance to first-generation EGFR-TKIs is a significant clinical challenge.

Purpose of the Study:

  • To review the role of EGFR-TKIs in advanced NSCLC management.
  • To discuss mechanisms of resistance to EGFR-TKIs.
  • To evaluate the clinical data and potential of afatinib in overcoming resistance.

Main Methods:

  • Review of pre-clinical and clinical trial data for afatinib.
  • Analysis of LUX-Lung trial results.
  • Discussion of EGFR and HER2 tyrosine kinase inhibition.

Main Results:

  • Afatinib is an oral, irreversible inhibitor of EGFR and HER2.
  • Pre-clinical and early-phase trials show a favorable safety profile and clinical activity.
  • LUX-Lung trials indicate symptomatic improvement and prolonged progression-free survival in selected patients.

Conclusions:

  • Afatinib represents a next-generation EGFR-TKI with potential to overcome resistance.
  • Selected NSCLC patients may benefit from afatinib in terms of symptom control and delayed progression.
  • Further research is needed to establish afatinib's impact on overall survival in advanced NSCLC.
Keywords:
EGFRLUX-Lungmutationtyrosine kinase inhibitor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K